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ABSTRACT 
 
NOTCH REGULATION OF ADAM12 EXPRESSION IN GLIOBLASTOMA 
MULTIFORME 
 
SEPTEMBER 2012 
ALA’A SALEM ALSYAIDEH, B.V.Sc. JORDAN UNIVERSITY OF SCIENCE AND 
TECHNOLOGY, JORDAN 
M.S. UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed by: Professor Lisa M. Minter 
Glioblastoma is the most common malignant brain tumor, accounting for 17% of 
all primary brain tumors in the United States. Despite the available surgical, radiation, 
and chemical therapeutic options, the invasive and infiltrative nature of the tumor render 
current treatment options minimally effective. Recent reports have identified multiple 
regulators of glioblastoma progression and invasiveness. It has been demonstrated that 
ADAM12, A Disintegrin And Metalloproteinase encoded by ADAM12 gene, is over-
expressed in glioblastoma and directly correlated with tumor proliferation. Additionally, 
dysregulation of the Notch signaling pathway has been implicated in the pathogenesis of 
many gliomas. Lastly, an evolving role of microRNAs, small noncoding RNAs, in 
carcinogenesis is progressively growing. A recent study has identified ADAM12 as a 
notch-related gene, and another demonstrated that inhibition of notch signaling decreased 
glioblastoma recurrence. However the mechanisms of regulation are still unknown. In 
this study, we hypothesize that direct downregulation of microRNA-29, downstream of 
over-expression of notch, enhances glioblastoma malignancy through upregulation of 
ADAM12. Although our data demonstrate upregulation of Notch1, its downstream target 
vii 
 
HES1, and ADAM12 in U87MG glioblastoma cell line. Expression of the cleaved 
intracellular Notch1 was not detected. Furthermore, we were unable to demonstrate an 
inhibitory effect of ɣ-secretase inhibitor on Notch signaling, likely reflecting the 
requirement for modifying culturing conditions or detection in our assays. Furthermore, 
miR-29 was detected in glioblastoma cells. The expression of miR-29 was further 
elevated by ɣ-secretase inhibitor treatment, suggesting a role for Notch1 inhibition on 
miR-29 expression. Although no conclusive results are shown in our work, a role of 
Notch1 through miR-29 is implicated in the pathogenesis of glioblastoma pathogenesis 
warranting further investigation into the role downstream target genes in the Notch 
signaling pathway. 
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CHAPTER 1 
THE ROLE OF NOTCH SIGNALING IN THE PATHOGENESIS OF 
GLIOBLASTOMA MULTIFORME 
 
1.1. Glioblastoma 
1.1.1. Introduction 
Gliomas are heterogeneous brain tumors with cellular features of glial cells and 
include astrocytomas, oligodendrogliomas, ependymoma, and mixed gliomas. Among the 
most aggressive subtypes is Glioblastoma Multiforme (GBM), the most aggressive of 
astrocytomas classified as Grade IV astrocytic neoplasm according to World Health 
Organization (WHO) (Louis et al., 2007). Histologically, GBM is characterized by 
increased cellularity, nuclear atypia, and mitotic activity similar to Grade III Anaplastic 
Astrocytoma, in addition to microvascular proliferation and necrosis unique to GBM 
(Figure 1) (Wen and Kesari, 2008). GBM is the most common primary brain neoplasm 
usually found in the cerebral hemispheres, but may also occur in the cerebellum, 
brainstem, or spinal cord (Schwartzbaum et al., 2006). Depending on the involved brain 
site, the most common clinical signs include seizures, headaches, and focal neurologic 
deficits. GBM accounts for 80% of all malignant brain tumors (CBTRUS, 2010). The 
causes of GBM are currently unknown; however, multiple risk factors, molecular 
pathways, and potential etiologies have been implicated in cellular transformations and 
tumorigenesis. Alcohol consumption, ionizing radiation, Simian virus 40 (SV40), and 
cytomegalovirus are among the most recent factors implicated in GBM pathogenesis 
(Baglietto et al., 2011; Cavenee, 2000; Dziurzynski et al., 2012; Vilchez et al., 2003).  
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Due to its infiltrative and necrotic potentials in addition to the uncontrolled cellular 
proliferation, angiogenesis, and resistance to apoptosis, GBM is associated with very 
poor prognosis (Furnari et al., 2007), with survival rates of only 4.5%  or less (CBTRUS, 
2010). Although combination of surgical, radiotherapy, and chemotherapy exists, the 
infiltrative nature of GBM leads to incomplete recovery and frequent fatal tumor relapse. 
This is primarily due to the difficulty in overcoming resistant cancer stem cells (CSCs). 
1.1.2. Cellular Origin 
GBM is composed of a mixed population of cell types that includes astrocyte-like 
and stem-like cells. The cellular origin of GBM is a controversial topic in glioma cancer 
research, and a continuous interest in GBM ontogeny is stimulated for the possibility of 
better understanding of fundamental pathways necessary for GBM development that 
could aid in improving diagnostic and therapeutic solutions (Visvader, 2011). One of the 
most significant recent advances in this regard is the discovery of cancer stem cells 
(CSC). For those pertaining to GBM, CSCs share multiple features with those found in 
normal neural stem cells and progenitor cells, such as self-renewal, marker expression, 
multilineage differentiation, and localization to stem cell microenvironment niches (Sanai 
et al., 2005). More recently, by introduction of genetic mutations into neural stem cells, 
several studies have supported the notion of neural stem cells in the production of GBM 
(Bachoo et al., 2002; Zheng et al., 2008; Zhu et al., 2005). Moreover, neural stem cells 
are probably target cells for malignant transformation, and the wide range in GBM 
heterogeneity represents different stages of neural stem cell differentiation hierarchy. 
Regardless, common features need to be met for a cell to be considered glioma CSC 
(Rich, 2008), which include capability of self-renewal, high proliferative potential, and 
when injected in xenograft models to initiate tumorigenesis. Despite the scientific 
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advances, it’s currently debatable whether CSCs originate from neural stem cells. CSCs 
are identified immunocytochemically by expression of CD133 (Assanah et al., 2006; 
Beier et al., 2007; Kesari and Stiles, 2006; Singh et al., 2004), and constitute a minority 
of the GBM cell population. Despite that, they play a critical role in tumor generation and 
maintenance, and contribute to tumor resistance to standard treatments (Dirks, 2008; 
Vescovi et al., 2006). 
1.1.3. Molecular Pathogenesis 
The mechanism of glial transformation is the result of cumulative genetic 
mutations and growth-factor signaling pathway dysregulation. Dysregulated signaling 
pathways frequently result in transcriptional activation of survival, proliferation, 
invasion, and angiogenesis pathways (Figure 2). 
1.1.3.1. Growth Factor Overexpression and Apoptosis 
Expression of both growth factors and their receptors is common in GBM and sets 
up an autocrine growth-promoting loop. The most common signaling defects occur in 
those that involve Epidermal Growth Factor Receptor (EGFR) and Platelet-derived 
Growth Factor Receptor (PDGFR) (Furnari et al., 2007). The A chain of PDGF and its 
cognate alpha receptor are overexpressed in the majority of diffuse astrocytic tumors 
(Hermanson et al., 1992). Amplification of EGFR expression on the other hand occurs 
primarily in GBM (Wen and Kesari, 2008). Upregulation of EGFR is reported in 40-50% 
of GBM patients, and half of those express a constitutively autophosphorylated EGFRvIII 
variant (Furnari et al., 2007; Pelloski et al., 2007). Aberrant growth factors result in 
activation of intermediate signal-transduction pathways; most commonly the Ras–
mitogen-activated protein (MAP) kinase pathway involved in proliferation and cell cycle 
progression, the phosphatidylinositol 3-kinase (PI3K)–Akt–mammalian target of 
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rapamycin (mTOR) pathways leading to the inhibition of apoptosis and enhancing 
cellular proliferation, and the inactivation of tumor-suppressor gene PTEN which 
negatively regulates the PI3K pathway (Furnari et al., 2007). 
1.1.3.2. Aberrant Cell Cycle 
Like other cancers, perturbations of p53- and Rb-mediated cell cycle regulation 
occur commonly in GBM. p53 protein normally inhibits cell cycle progression and 
induces apoptosis in response to DNA damage, and hence inactivation of p53 function 
leads to cell cycle dysregulation. Mutation in p53 is reported in approximately 25% of 
GBMs (Fulci et al., 1998). Aberrant loss of Rb and other components of the 
p16/cdk4/cyclinD/pRb G1 to S phase transition cell cycle regulation are frequently 
observed in GBM and other astrocytic tumors. Mutation in Rb occurs in 30–40% of 
GBMs, and mutation in p16 occurs in 33% of GBM. Disturbance of this check point 
results in uncontrolled cell cycle and progression of tumor formation.  
1.1.3.3. Angiogenesis and Invasion 
GBM is a markedly vascularised cancer and characterized by significant 
invasiveness of the surrounding brain parenchyma. This is heavily regulated through 
crosstalk between growth factors, extracellular matrix proteins, integrins, proteinases, and 
tissue microenvironment. Angiogenic and invasive features of GBM result from a 
combination of stimulating factors, such as activation of vascular endothelial growth 
factor (VEGF) and Matrix Metalloproteinases (MMPs) (Guo et al., 2003; Jain et al., 
2007), that aid in neovascularization and breakdown of impeding extracellular matrix 
proteins, and degradation of normally inhibiting factors, such collagen, leading to local 
tumor spread and access to the systemic circulatory system.  
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1.1.3.4. Other signaling pathway 
Other developmental pathways that contribute to the biologic features of gliomas 
are those involving Notch, sonic hedgehog, wingless, CXC chemokine receptor 4 
(CXCR4), and bone morphogenetic proteins (Lee da and Gutmann, 2007). In the 
following section, we will review details on Notch biology and its contribution to GBM 
tumorigenesis. 
1.2. Notch 
1.2.1. Biology 
The “Notch” family of proteins was initially identified by Thomas Morgan in 
Drosophila melanogaster in 1917. Mutation in the genes encoding Notch proteins 
resulted in ‘notches’ at the wing margin of adult flies, hence inspiring the Notch name 
(Morgan, 1917). Notch proteins are type I transmembrane receptors consisting of 36 
ligand binding epidermal growth factor (EGF)-like tandem repeats and 3 LIN-12/Notch 
(LIN) repeats in the extracellular domain. The intracytoplasmic domain contains RBPJκ-
binding (RAM) domain, six tandem ankyrin (ANK) repeats, a transcription activation 
domain (TAD) and a proline/glutamate/serine/threonine-rich (PEST) sequence (Figure 3) 
(Tsukumo and Yasutomo, 2004). Notch receptor is cleaved post-translationally at site S1 
and heterodimerized between two extracytoplasmic juxtamembrane regions that form 
both N-terminal and C-terminal heterodimerization domains (HD-N and HD-C, 
respectively) to generate a fully mature receptor. In vertebrates, four Notch paralogs are 
encoded (Notch 1-4), with Notch1 and Notch2 showing high homology with Drosophila 
Notch, and Notch3 and Notch4 are more distantly related, with 34 and 29 EGF-like 
repeats, and are devoid of TAD domains (Lardelli et al., 1994; Uyttendaele et al., 1996; 
Weinmaster et al., 1991; Weinmaster et al., 1992). 
6 
 
1.2.2. Notch signaling 
In mammals, Notch receptors are activated by five type I transmembrane ligands, 
three Delta-like (Dll1, Dll3 and Dll4) and two Serrate/Jagged (Jag 1 and Jag2) (Figure 3) 
(Artavanis-Tsakonas et al., 1999). 
Notch activation results from ligand-mediated cleavage at sites S2 or S3 (Figure 
4). Activation of Notch from cleavage at site S3 within the transmembrane domain is 
mediated by gamma-secretase (De Strooper et al., 1999). Receptor activation leads to 
release of Notch intracellular domain (NICD), which translocate to the nucleus. 
Thereafter, intranuclear NICD binds Su(H)/CSL/CBF1/RBPJκ to trans-activate target 
genes such as HES and HEY families of basic helix-loop-helix transcription factors 
(Artavanis-Tsakonas et al., 1995; Artavanis-Tsakonas et al., 1999; Jarriault et al., 1995). 
Cleavage of Notch at site S2 is mediated by an ADAM metalloprotease and TNF-α-
converting enzyme (TACE) (Brou et al., 2000), and leads to the release of a soluble form 
of Notch named Notch extracellular truncation (NEXT) (Mumm et al., 2000). 
Non-canonical Notch signaling can occur independent of RBPJκ, presumably 
through a Deltex-dependent alternative pathway (Matsuno et al., 1998; Ramain et al., 
2001). In T helper (Th) cells, Jagged mediates Th2 cell differentiation by triggering the 
RBPJκ-dependent canonical pathway, while Dll1 instructs Th1 commitment in an 
RBPJκ-independent fashion (Amsen et al., 2004). 
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1.2.3. Notch in Brain Development 
The Notch signaling pathway plays a fundamental role in the regulation of several 
developmental processes such as proliferation, stem cell maintenance, differentiation 
during embryonic development and homeostasis of adult self-renewing organs (Bray, 
2006; Wen and Kesari, 2008). Canonical and non-canonical Notch signaling pathways 
have been shown to target several genes involved in brain development. The canonical 
pathway has been shown to target GFAP (Ge et al., 2002), HES1 (Wu et al., 2003), 
HEY1 (Zavadil et al., 2004), BLBP (Patten et al., 2003), NESTIN (Shih and Holland, 
2006), and TNC genes (Sivasankaran et al., 2009), while the non-canonical pathway has 
been shown to target ERBB2 (Patten et al., 2006). Most importantly, Notch1 induces 
TP53-dependent EGFR expression (Purow et al., 2008), the most common signaling 
defect in GBM. 
In addition to the “notched” winged observed in Drosophila melanogaster with 
mutated Notch genes, several studies have demonstrated the role of Notch in 
neurogenesis. In loss-of-function experiments, a defective neuroectodermal development 
was observed, with the development of an embryonic phenotype characterized by 
expanded population of neuroblasts at the expense of epidermal cells (Poulson, 1937). 
This indicated that Notch is an antineurogenic factor required to control cell fate decision 
by preventing the differentiation into neuroblasts. Gain-of-function mutation in Notch 
gene further supported the antineurogenic role of Notch during Drosophila development 
(Brennan et al., 1997; Rebay et al., 1993).  
Distinct patterns of Notch expression are seen in rodents. While notch1, notch2, 
and notch3 transcripts are commonly present in the germinal zones of late embryonic and 
postnatal brains, notch2 expression persists in the postnatal mouse brain in immature glial 
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cells (Higuchi et al., 1995; Irvin et al., 2001; Tanaka et al., 1999). Consistent with the 
antineurogenic role of Notch signaling in Drosophila, it appears that high expression of 
Notch2 is required for the prevention of neuronal differentiation and the maintenance of 
neural stem cell (NSC). Activation of Notch promoted gliogenesis at the expense of 
neurogenesis (Morrison et al., 2000), and suppressed neuronal differentiation of NSCs by 
maintaining their proliferation (Hitoshi et al., 2002; Shimizu et al., 2008; Solecki et al., 
2001). These observations suggest a role for Notch signaling in the maintenance of GBM 
CSC. 
While knockout of Notch1 and Notch2 in results in embryonic and perinatal 
lethality, mutations in Notch have been associated with neurological and vascular 
abnormalities in humans (Garg et al., 2005; Joutel et al., 1996). The fact that the Notch 
signaling pathway is involved in several developmental processes and that inactivation of 
Notch results in constant defects in angiogenesis implicate a possible role for Notch 
signaling in tumorigenesis and tumor neovascularization. This is evident in the role of 
Notch1 and Notch2 mutations found in acute T cell lymphoblastic leukemia (T-ALL) and 
a fraction of B cell lymphomas, respectively (Ellisen et al., 1991; Lee et al., 2009). 
1.2.4. Notch in Glioblastoma 
Notch signaling is one of the major pathways involved in GBM development, and 
expression of Notch proteins and their ligands are critical markers of GBM survival and 
proliferation (Boulay et al., 2007; Purow et al., 2005). 
Notch1 and Notch2 are highly expressed in GBM and astrocytoma (Sivasankaran 
et al., 2009). Notch2 has been suggested to drive embryonic brain tumor growth (Solecki 
et al., 2001), with high expression in GBM (Sivasankaran et al., 2009). Through TP53, 
Notch1 was shown to regulate transcription of the EGFR gene, the major proliferation 
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pathway in GBM (Purow et al., 2008), with overexpression of Notch signaling mediator 
genes in the molecular subset of GBM with EGFR amplification (Brennan et al., 2009). 
In contrast, a minor subset of GBM with slower GBM progression and better patient 
prognosis are associated with impaired Notch2 signaling and impaired Notch-mediated 
GBM invasiveness (Boulay et al., 2007; Sivasankaran et al., 2009). The role of Notch 
was further supported by loss-of-function and gain-of-function experiments. While 
inhibition of Notch signaling by the use of ɣ-secretase inhibitors (GSIs) resulted in 
reduction in GBM CSC proliferation and increased apoptosis, while expression of an 
active form of Notch2 increased tumor growth (Fan et al., 2009). Interestingly, in vivo 
delivery of GSI consistently blocked tumor growth, and significantly prolonged patient 
survival (Fan et al., 2009). Through the inhibition of Notch signaling, GSI treatment 
significantly reduced radioresistance of GBM CSC (Wang et al., 2009). 
Additionally, Notch-RBPJκ transactivates tenascin-C (Sivasankaran et al., 2009), 
a highly expressed extracellular matrix glycoprotein that increases during progression of 
GBM and used as a prognostic marker for GBM patient survival (Garcion et al., 2001; 
Leins et al., 2003).  
1.3. MicroRNAs 
1.3.1. Signaling and processing of miRNAs 
MicroRNAs (miRNAs) are a non-coding class of RNAs, 20-25 nucleotides in 
length that do not result in proteins. MicroRNAs modulate gene expression through base 
pairing between the seed sequence of the miRNA (nucleotides 2-8 at its 5' end) and their 
complementary match sequence at the 3' UTR region of target mRNAs (Bartel, 2009). 
Cognate binding of miRNA to its target mRNA results in translation suppression or direct 
degradation of targeted mRNA (Kolfschoten et al., 2009). MicroRNAs are first 
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transcribed as long (~ 250 nts) primary transcripts (pri-miRNA) that fold into hairpin-like 
structures. Following transcription, primary transcripts are processed in the nucleus by 
the Drosha complex into pre-miRNAs (~120 nts) and transported to the cytoplasm by 
exportin 5. In the cytoplasm, pre-miRNAare further processed by Dicer ribonuclease 
(Carthew and Sontheimer, 2009), in which mature miRNAs are incorporated into the 
RNA-induced silencing complex (RISC) in association with Argonaute proteins. Single-
stranded miRNA is unwound by Dicer, which also guides target selection, inhibiting the 
translation, and stability and/or localization of target mRNA (Brodersen and Voinnet, 
2009; Kim et al., 2009; Zheng et al., 2008). MicroRNA biogenesis and mRNA binding is 
illustrated in figure 5. 
1.3.2. Structure and function of the miR-29 family 
The microRNA-29 (miR-29) family in human consists of four members: miR-
29a, miR-29b1, miR-29b2, and miR-29c. They are encoded by two gene clusters, MIR-
29B1-MIR-29A and MIR-29B2-MIR-29C located in chromosome 7 (chr.7q32.3) and 
chromosome 1 (chr.1q32.2), respectively (Kriegel et al., 2012). miR-29b1 and miR-29b2 
are identical, but they are distinguished from each other due to their chromosomal 
location. The distance between the two miRNAs in each cluster is less than 1kb (Chang et 
al., 2008; Eyholzer et al., 2010; Mott et al., 2010), and miR-29b1 and miR-29b2 are 
upstream of miR-29a and miR-29c, respectively the gene sequences are highly conserved 
between humans, rats and mice. The mature sequences of miR-29a and miR-29c are 22 
nucleotides long while miR-29b1/b2 have identical mature sequences and are 23 
nucleotides long. Each of miR-29 members have the same short seed sequence; 
AGCACC between positions 2 to 7 in each mature sequence. Consequently, it is 
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predicted that all miR-29 members target the same set of genes. The structures of pre-
miR-29 and mature miR-29 are shown in Figure 6. 
1.3.3. The miR-29 family in tumorigenesis 
Similar to mRNAs encoding for proteins, miRNAs have well-defined 
developmental and cell-type-specific expression patterns, and may be involved in tumor 
suppression or tumor malignancies (Havelange et al., 2009). 
Loss of miR-29 function has been associated with several tumors. Mutated miR-
29b has been shown in leukemia, and mutation repair prevented the ability of leukemia 
cells from growing in an immunodeficient mouse host (Havelange et al., 2009). 
Upregulated miR-29a and miR-29b were also found in B-cell Chronic Lymphocytic 
Leukemia (CLL) (Santanam et al., 2010). Elevated miR-29a expression and 
downregulation of miR-29b were found in primary Acute Myeloid Leukemia (AML) 
(Garzon et al., 2008; Han et al., 2010). Reduced expression of miR-29b has been 
observed in hepatocellular carcinoma and is significantly associated with poor prognosis. 
Re-introduction of miR-29a/b/c induced apoptosis of cancer cells and repressed 
tumorigenicity (Xiong et al., 2010). miR-29b was similarly found downregulated in 
cholangiocarcinoma cell lines (Mott et al., 2007). Furthermore, miR-29 was found to 
function in myogenesis and is epigenetically silenced in rhabdomyosarcoma cell lines 
(Wang et al., 2008). Upregulation of miR-29a/b/c expression was also found in 
pancreatic endocrine tumors (Roldo et al., 2006).   
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Figure 1: Histological features of Glioblastoma Multiforme. Panels A and B show the 
histologic appearance of a glioblastoma, characterized by nuclear pleomorphism, dense 
cellularity, and pseudopalisading necrosis (asterisk) (Panel A, hematoxylin and eosin), as 
well as vascular endothelial proliferation (asterisk) and mitotic figures (arrows) (Panel B, 
hematoxylin and eosin) (Wen and Kesari, 2008). 
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Figure 2: Major Signaling Pathways in Malignant Gliomas and the Corresponding 
Targeted Agents in Development for Glioblastoma (Wen and Kesari, 2008). 
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Figure 3: Ligands, structure and processing of Notch1 receptor. Left: the Delta-like 
ligand (Dll) and Serrate-Jagged ligand (Jag) structural subsets of Notch ligands. Right: 
structure of Notch1 receptor resulting from post-translational cleavage at site S1 and 
heterodimerization of the cleaved parts. Ligand-dependent cleavages at sites S2 and S3 
generate soluble Notch extracellular truncation (NEXT) and cytosolic Notch intracellular 
domain (N-IC) forms, respectively (Lino et al., 2010). 
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Figure 4: Sequential events and control of Notch expression and signaling (Osborne 
and Minter, 2007). 
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Figure 5.Schematic of microRNA biogenesis. (A) Biogenesis of a miRNA-induced 
silencing complex (RISC). (B) Binding of microRNA to the 3'-UTR of mRNA (Liu, 
2009). 
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Figure 6: Structure of pre-miR-29 and mature miR-29 family of microRNAs. The structure of (A) miR-29a, (B) miR-29b and (C) 
miR-29c. 
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1.4. AIM of the study 
1.4.1. Rationale 
Recent reports have identified multiple regulators of glioblastoma progression and 
invasiveness. It has been demonstrated that ADAM12, A Disintegrin and 
Metalloproteinase encoded by ADAM12 gene, is over-expressed in glioblastoma and 
directly correlated with tumor proliferation. Additionally, dysregulation of the Notch 
signaling pathway has been implicated in the pathogenesis of many gliomas. Lastly, an 
evolving role of microRNAs in carcinogenesis is progressively growing. A recent study 
has identified ADAM12 as a Notch-related gene, and another demonstrated that inhibition 
of Notch signaling decreased glioblastoma recurrence. However the mechanisms of 
regulation are still unknown.  
1.4.2. Hypothesis 
In this study, we hypothesize that direct downregulation of microRNA-29, 
downstream of over-expression of Notch, enhances glioblastoma malignancy through 
upregulation of ADAM12. 
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CHAPTER 2 
RESULTS 
 
2.1. Assay optimization for the detection of Notch1 in GBM cell line 
For optimal detection of Notch1 and ADAM12 in GBM cell line, U87MG cells 
were plated at different cellular density at two culture durations. Cells were cultured at 
0.25X106, 0.5X106, and 1X106 cells per well in 6-well plates and were incubated at 
37˚C/5%CO2 for 24 hours and 48 hours. Cells were harvested and examined by trypan 
blue viability assay as indicated in the Materials and Methods section.  
As shown in Table 1, all culture conditions resulted in an increase in the total 
number of cells after 24 and 48 hours of culture initiation. While the percent viability was 
high in all conditions, initial culture start of 0.25X106 cells for 24 hours results in the 
most remarkable cell death and lowest viability percentage at 57.1% despite the increase 
in total number of cells 24 hours post culture initiation. Viability percentage of initial 
0.25X106 cells condition was higher at 48 hours post culture initiation. Culturing cells at 
0.5X106 and 1X106 resulted in cellular expansion and comparable high viability rates at 
both 24 and 48 hours. 
2.2. Expression of Notch1, ADAM12, and miR-29 in GBM cell line 
The Notch signaling pathway has been implicated in the pathogenesis of GBM. 
To examine the expression of Notch signaling pathway components in U87MG GBM cell 
line, Notch1, HES1, and c-myc expression levels were determined at the protein and 
mRNA levels. Additionally, ADAM12 expression levels were determined to correlate 
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their expression levels with components of the Notch signaling pathway. Cell culture 
conditions of 0.3X106 per well were plated in a 6-well plate and incubated for 24, 48, and 
72 hours to monitor the differential Notch1 and ADAM12 protein expressions at different 
time points (Figure 7). Notch1-specific antibody used in these verification experiments is 
able to detect the C-terminus of Notch1 present in uncleaved Notch1 and the 
transmembrane domain post Notch1 activation. Our ADAM12-specific antibody is able 
to detect both the long and short forms of ADAM12 . Jurkat cells were used as a positive 
control for the detection of Notch1 and ADAM12, and DO11.10 were used as a negative 
control for Notch1 expression.  
Both total Notch1 (300kDa, not shown) and the cleaved transmembrane domain 
of Notch1 (120kDa) were detected at all time points in both the GBM U87MG cell line 
and in the positive control Jurkat cell line. Two bands were present in the negative 
control DO11.10 cell line; however, these bands don’t correspond to the expected band 
sizes of Notch1 and hence likely represent non-specific cross reactivity. The downstream 
components of the Notch signaling pathway, HES1 and c-myc, were detected in U87MG 
cell line by western blot analysis (data not shown). ADAM12 was equally detected at all 
time points, correlating with the upregulated expression of Notch signaling pathway 
components. Adequate protein extraction and equal protein loading per lane were 
confirmed by the strong and equal band density of the positive internal control β-Actin.   
To verify the activity of the Notch signaling pathway at the transcriptional levels, 
mRNA expression of NOTCH1, HES1, and the long (ADAM12L) and short (ADAM12S) 
forms of ADAM12 were measured using the same culture conditions (Figure 8). 
NOTCH1, HES1, ADAM12L, and ADAM12S were detected to levels comparable to the 
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positive internal control β-ACTIN, indicating the activation of these genes in U87MG 
GBM cell line. Transcript levels of all genes remained relatively constant at 24, 48, and 
72 hours post culture initiation. ADAM12L expression was higher compared to ADAM12S 
and NOTCH1, the latter of which had comparable expression levels.  
We further demonstrated the specificity and sensitivity of our culture conditions 
and assay design for the detection of members of the miR-29 family, miR-29a, miR-29b, 
and miR-29c, a group of microRNAs that are modulated by Notch1 activation in certain 
types of tumors (Figure 9). Sno202 was used as an internal control, and it was detected in 
all culture conditions. All members of the miR-29 family were detected in our assay to 
levels below sno202. When compared to each other, levels of miR-29a, miR-29b, and 
miR-29c were comparable at all time points. In general, the expression levels of all miR-
29 members were approximately 50% of the expression level of the internal control 
sno202.  
Repetition of the same quantitative RT-PCR work with lower cell density per well 
at 0.2X106 cells per well in 6-well plate resulted in similar expression levels of NOTCH1, 
HES1, ADAM12L, and ADAM12S (Figure 10). Although miR-29 expression was detected 
at lower cell culture density, the expression levels were nearly 1.3 fold higher compared 
to their corresponding expression levels at 0.3X106 cells per well.  Despite lower viability 
rates at lower cell density, expression levels remained comparable between the two 
culture conditions. Regardless, our results demonstrate that our culture conditions and 
detection assays are sufficient and capable of detecting variable protein and transcript 
levels of Notch1, HES1, ADAM12, and members of miR-29 family. 
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2.3. The effect of gamma-secretase inhibitor on the expression of Notch1, HES1, 
ADAM12, and miR-29 in GBM cell line 
To explore the regulation of Notch signaling pathway in GBM, we treated 
U87MG GBM cell line with ɣ-secretase inhibitor (GSI), an inhibitor of Notch cleaving 
enzyme ɣ-secretase, and measured gene transcription levels of components of the Notch 
signaling pathway. Using western blot analysis, full-length Notch1 and the cleaved 
transmembrane component of Notch1 were readily expressed in U87MG cells (Figure 
11). The cleaved intracellular component of Notch1 however was not detected. Similarly, 
ADAM12 was detected in cells. Treatment of cells with GSI did not affect the protein 
expression levels of Notch1 or ADAM12. Repeating the same experiment at longer 
durations of 48h and 72h with longer and higher concentrations of GSI treatment did not 
result in any difference in the Notch1 and ADAM12 expression levels, and the cleaved 
intracellular domain remained undetectable. 
To verify the effectiveness of GSI treatment, similar conditions were carried out 
on Jurkat cell line, cells known to constitutively express high levels of the cleaved 
intracellular component of Notch1 and respond to GSI treatment (Figure 12A). Indeed, 
the cleaved intracellular component of Notch1 was detected in untreated Jurkat cells. 
Moreover, treatment of cells with multiple preparations of GSI resulted in significant 
downregulation of the cleaved intracellular component of Notch1 as expected. These 
results demonstrate that our culture setup and treatment are functioning properly. We 
then tested the same GSI preparations on U87MG GBM cell line (Figure 12B). While the 
Notch1 and ADAM12 were expressed, the cleaved intracellular component of Notch1 
was not expressed. Furthermore, treatment of cells with different GSI preparations for 
48h did not result in changes in the levels of Notch1 or ADAM12 expression. These 
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results demonstrate that Notch1 has been cleaved, as detected by the cleaved 
transmembrane component, the cleavage of Notch1 did not result in an intracellular 
component, suggesting one of the following scenarios: (1) that cleaved intracellular 
component of Notch1 rapidly degraded to levels below our assay limits of detection in 
whole cell lysate and that Notch1 enrichment in nuclear protein fraction is necessary for 
the detection of low levels of cleaved intracellular Notch1, or that (2) Notch1 was 
cleaved at a site alternative to V1744, rendering our detecting monoclonal antibody non-
specific for the detection of newly formed cleaved Notch1 in our western blot analysis. 
To further investigate the expression of the Notch signaling pathway at the 
transcriptional levels using our quantitative RT-PCR assay. Relative to β-ACTIN 
expression, the expression of NOTCH1 transcript levels increased with GSI treatment 
(Figure 13A). NOTCH1 expression levels were highest at 72h post treatment, with 
expression levels at least 4 fold higher compared to β-ACTIN expression and 10 fold 
higher with 50µM GSI treatment. The expression of HES1, ADAM12L, and ADAM12S 
were similar to those seen with NOTCH1. HES1 expression was 3-20 fold higher than β-
ACTIN expression, particularly with 5µM and 50µM GSI treatment at 24h and 72h post 
treatment (Figure 13B). Levels of ADAM12L were at least 2 fold higher than β-ACTIN 
expression; however, this was only seen with 72h of culture treatment (Figure 13C). 
ADAM12S was similarly expressed at high levels, particularly with 5µM and 50µM GSI 
treatment at all time points (Figure13D). These results demonstrate difference between 
the transcriptional and protein levels of the examined genes, and indicate that the mode of 
regulation in U87MG GBM cell line needs to be explored. 
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In an attempt to investigate the regulation of the aforementioned genes, we 
measured the expression levels for members of the miR-29 family. Levels of miR-29a, 
miR-29b, and miR-29c were constantly elevated compared to the internal control (Figure 
14). Levels of miR-29b and miR-29c at 72h post treatment were the highest. Although 
further work is needed to investigate the nature of miR-29 involvement in GBM 
pathogenesis, the elevated levels of miR-29 members support their role in GBM 
pathogenesis. 
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Table 1. Viability Assay of U87MG cell line at 24 and 48 hour. 
24 HOUR CULTURE 
ORIGINAL 
NUMBER  
TOTAL 
LIVE  
TOTAL 
DEAD  
TOTAL 
ALL  % VIABLE  
% 
DEAD  
0.25X106  2.0X105 1.5X105 3.5X105 57.1  42.9  
0.5X106 5.5X105 1.0X105 6.5X105 84.6  15.4  
1.0X106 1.1X106 7.5X104 1.1X106 93.3  6.7  
48 HOUR CULTURE 
ORIGINAL 
NUMBER  
TOTAL 
LIVE  
TOTAL 
DEAD  
TOTAL 
ALL  % VIABLE  
% 
DEAD  
0.25X106  3.5X105 1.0X105 4.5X105 77.8  22.2  
0.5X106 5.8X105 5.0X104 6.3X105 92.0  8.0  
1.0X106 1.2X106 2.5X105 1.5X106 83.1  16.9  
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Figure 7: Expression of Notch1 and ADAM12 in U87MG GBM cell line. Western 
blot analysis of protein levels of Notch1 and ADAM12 in U87MG GBM cell line at 24h, 
48h, and 72h of culture. Jurkat cells were used as a positive control for the expression of 
Notch1 and ADAM12 and DO11.10 cells were used as a negative control for the 
expression of Notch1. 
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Figure 8: Expression of NOTCH, HES1, and ADAM12 in U87MG GBM cell line. 
Quantitative RT-PCR analysis of transcription levels of NOTCH1, HES1, and ADAM12 
in U87MG GBM cell line at 24h, 48h, and 72h of culture. Results were generated from 3 
independent experiments, calculated by the ΔΔCT method, and normalized to β-Actin. 
Each bar represents the mean ± standard error of the mean [SEM]. 
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Figure 9: Expression of miR-29 family in U87MG GBM cell line. Quantitative RT-
PCR analysis of transcription levels of miR-29a, miR-29b, and miR-29c in U87MG 
GBM cell line at 24h, 48h, and 72h of culture. Results were generated from 3 
independent experiments, calculated by the ΔΔCT method, and normalized to sno202. 
Each bar represents the mean ± standard error of the mean [SEM]. 
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Figure 10: Expression of NOTCH1, HES1, ADAM12, and miR-29 family at two 
different cell densities of U87MG GBM cell line. Quantitative RT-PCR analysis in 
U87MG GBM cell line at 0.2X106 and 0.3X106 cells per well. Results were generated 
from 3 independent experiments, calculated by the ΔΔCT method. mRNA data were 
normalized to β-ACTIN, and miRNA data were normalized to sno202. Each bar 
represents the mean ± standard error of the mean [SEM].*P <0.05; *** P <0.001; **** 
P <0.0001  
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Figure 11: Effect of GSI on the expression of Notch1, cleaved intracellular Notch1, 
and ADAM12 in U87MG GBM cell line. Western blot analysis of protein levels of 
Notch1, cleaved intracellular Notch1, and ADAM12 in U87MG GBM cell line at 24h, 
48h, and 72h of culture treated with 5, 10, 20, and 50µM of DAPT-GSI. Jurkat cells were 
used as a positive control for the expression of Notch1, cleaved intracellular Notch1, and 
ADAM12L and DO11.10 cells were used as a negative control for the expression of 
Notch1. 
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Figure 12: Effects of different GSI preparations on Notch1 activation.(A)Western 
blot analysis of protein levels of cleaved intracellular Notch1 in Jurkat cell line at 24h of 
culture treated with 10 and 50µM of two preparations of DAPT-GSI and one preparation 
of IL-CHO-GSI.(B) Western blot analysis of protein levels of Notch1, cleaved 
intracellular Notch1, and ADAM12 in U87MG GBM cell line at 48h of culture treated 
with 5, 25 and 50µM of DAPT-GSI and IL-CHO-GSI.  
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Figure 13: Effects of GSI on the expression of Notch1, cleaved intracellular Notch1, 
and ADAM12 in U87MG GBM cell line. Quantitative RT-PCR analysis in U87MG 
GBM cell line at 0.3X106 cells per well and treated with 5, 25, and 50µM DAPT-GSI for 
24h, 48h, and 72h. Results were generated from 3 independent experiments, calculated by 
the ΔΔCT method and normalized to β-Actin. Each bar represents the mean ± standard 
error of the mean [SEM].  
A B 
C D 
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Figure 14: Effects of GSI on the expression of miR-29 in U87MG GBM cell line. 
Quantitative RT-PCR analysis in U87MG GBM cell line at 0.3X106 cells per well and 
treated with 5, 25, and 50µM DAPT-GSI for 24h, 48h, and 72h. Results were generated 
from 3 independent experiments, calculated by the ΔΔCT method and normalized to 
sno202. Each bar represents the mean ± standard error of the mean [SEM]. 
  
A 
B 
C 
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CHAPTER 3 
DISCUSSION AND CONCLUDING REMARKS 
 
The association of Notch signaling pathway with the pathogenesis of many types 
of cancers has been previously demonstrated (Leong and Karsan, 2006). Here, we 
investigated Notch1 regulation of ADAM12 in the U87MG Glioblastoma cell line, to aid 
in our understanding of the pathogenesis of GBM, the most malignant type of brain 
cancer. We demonstrated elevated levels of Notch1, HES1, c-Myc, and ADAM12 
expression levels in U87MG GBM cell line, indicating that the Notch signaling pathway 
is activated in GBM and correlates with the expression level of ADAM12 protein 
expression. We further confirmed the elevated expression of NOTCH1, HES1, and 
ADAM12 in GBM cell line at the transcriptional level using quantitative RT-PCR. 
To examine the downstream components of the Notch signaling pathway, we 
examined the expression levels of cleaved intracellular Notch1, HES1, and ADAM12. 
While our results demonstrated that Notch1 had been cleaved, as detected by the cleaved 
transmembrane component, we were unable to detect cleaved intracellular component, 
suggesting a dysfunction in the cleavage at the S2 cleavage site limiting the exposure of 
S3 cleavage site and resulting in a cleaved transmembrane with absence of the 
intracellular domain. Alternatively, there might be a different species of intracellular 
cleaved Notch that might have resulted from cleavage at a site different from the 
originally accepted V1744 site (Tagami et al., 2008), resulting in failure of our antibody, 
which only detects Notch1 cleaved at V1744, to detect the intracellular cleaved form of 
Notch1. Transcriptional levels of these genes on the other hand were elevated with 
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treatment of GSI, an inhibitor of intracellular Notch cleavage, indicating an upregulation 
of gene expression with post-transcriptional suppression of translation. The difference 
between the transcriptional and protein levels of the examined genes requires additional 
exploration of the mode of regulation in GBM. Furthermore, multiple types of GSI 
investigational drugs exist that potentially target different isoforms of ɣ-secretase present 
in GBM cell lines and different from those present in our Jurkat cells positive control 
(Kopan and Ilagan, 2009). Alternative experimental approaches can be potentially used to 
suppress Notch signaling pathway, such as siRNA against Notch mRNA or the 
expression of dominant negative form of Notch coactivator mastermind-like 1 (Chen et 
al., 2010). 
Similarly, transcriptional levels of miR-29 members were elevated in U87MG 
GBM cell line, indicating their involvement in GBM pathogenesis. It is possible that the 
elevated miR-29 levels results in posttranscriptional suppression of ADAM12 translation, 
hence explaining the elevated ADAM12 transcripts with no demonstrable elevation of 
ADAM12 protein levels upon GSI treatment. A similar mechanism might be involved in 
the regulation of Notch1 translation. 
The involvement of Notch signaling pathway in brain development and cancer is 
highly context-dependent (Lardelli et al., 1994). Previous reports have demonstrated the 
differential expression of various Notch signaling components in GBM (Chen et al., 
2010). Although all cell lines used were derived from GBM patients, the role of Notch 
signaling differed according to GBM subtype. In contrast to our results, Notch2 was the 
predominant Notch type involved in the majority of GBM subtypes, including U87 cell 
line. Notch1 expression was predominant in only 2 of the 5 cell line examined. While the 
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authors demonstrated the biological effect of Notch signaling on tumor growth and 
neurosphere formation, they similarly failed to present the expression of cleaved 
intracellular Notch domain. It is then likely that Notch exerts its function in GBM 
through a different pathway that does not induce the expression of cleaved intracellular 
Notch domain, or that we are temporally unable to detect that component in our culture 
conditions due to a short half-life of the cleaved protein. 
Other studies have indicated that Notch signaling increases neurosphere formation 
(Fan et al., 2010; Gilbert et al., 2010; Jeon et al., 2008), the cancer stem cell component 
of GBM, indicating the need to test our parameters in neurosphere culturing conditions, 
which include serum depletion of culture media and longer culturing durations of up to 
10 days. 
In all, our study supports the role of Notch signaling pathway in GBM 
pathogenesis and support further investigation in the role of ADAM12 and miR-29 in the 
pathogenesis of GBM.  
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CHAPTER 4 
MATERIALS AND METHODS 
 
4.1. Cell Culture 
U87MG and Hela cells were cultured in EMEM. DO11.10 cells were cultured in RDG 
complete media composed of 45% RPMI 1640 and 45% DMEM. Jurkat cells were 
cultured in RPMI 1640 supplemented with 1% L-glutamate, 1% Na pyrovate, and 2-
mercaptoethanol. All culture media were supplemented with 10% FBS and 1% penicillin-
streptomycin (Lonza, Switzerland) and incubated at 37°C, 5% CO2. Hela, Jurkat, and 
DO11.10 cells were cultured to 80% confluence for protein extraction. U87MG cells 
were plated as described in “Compound Treatment” section below. 
4.2. Viability Analysis 
U87MG cells were cultured at 0.2X106, 0.5X106, and 1X106 for 24h and 48h. At the end 
of each time point, 0.5 ml of a cell suspension was placed in a screw cap test tube and 
mixed thoroughly with 0.1 ml of 0.4% Trypan Blue Stain. Cells were allowed to stand 5 
min at room temperature.  Dead cells, stained blue, were counted in a hemocytometer 
under a microscope. Percentage of viable cells was calculated by dividing the total 
number of unstained cells over the total number of cells. 
4.3. Compound treatment 
U87MG cells were plated at different cell numbers, as discussed in the results sections, in 
2ml growth medium per well in 6-well plate. Twenty four hours later, cells were treated 
with 2, 5, 10, 20, 25, and 50 μM (in DMSO) of GSI inhibitors cbz-I-L-CHO (zIL-CHO) 
or N-[N-(3, 5-difluorophenacetyl)-l-alanyl]-5-phenylglycine t-butyl ester (DAPT) 
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(Sigma-Aldrich) for 24, 48, and 72 hours. Additional wells were either left untreated or 
treated with comparable volumes of DMSO (Sigma-Aldrich). 
4.4. Protein Extraction 
Whole cell lysates were prepared by lysing cells using RIPA buffer (50mM Tris, pH8.0, 
150mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors). 
For subcellular fractionation, total cellular protein was separated into cytoplasmic and 
nuclear fractions using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo 
Scientific), according to manufacturer’s directions. Protein concentrations were measured 
using BCA Assay kit according to manufacturer’s directions (Thermo Scientific). 
4.5. Antibodies and Western Blot Analysis 
Thirty to fifty micrograms of protein were separated by electrophoresis in 8% SDS-
polyacrylamide gels. Proteins were electrotransferred to polyvinylidenedifluoride 
membranes (PVDF) (Millipore, Bedford, MA), while either immersed in 1X transfer 
buffer (wet transfer) or without transfer buffer (semi-dry transfer), and probed with the 
indicated primary antibodies as shown in table 2. Horseradish peroxidase-conjugated 
donkey anti-rabbit and sheep anti-mouse secondary antibodies (GE Health, Piscataway, 
NJ) were used at a dilution of 1:2500, and bands were detected with enhanced 
chemiluminescence (ECL, Thermo Scientific). Loading was normalized with β-Actin 
(Sigma-Aldrich) for total and cytoplasmic proteins, or Histone Deacetylase 1 (HDAC1) 
for nuclear proteins. Solution for blocking membranes and for primary and secondary 
antibody dilutions (BLOTTO) was made from 1X PBS containing 0.1% Tween-20 
supplemented with 5% (wt/vol) dry fat-free milk powder (Carnation Nestle). 
  
39 
 
Table 2: Primary Antibody List 
Antigen Species Clone Dilution Source 
Notch1 Rabbit sc-6014R 1:200 Santa Cruz 
Notch1 Mouse mN1A 1:1000 eBioscience 
Cleaved Notch1 Rabbit Polyclonal 1:1000 Cell Signaling 
ADAM12 Rabbit Polyclonal 1:1500 Proteintech 
Hes1 Rabbit Polyclonal 1:1000 Santa Cruz 
c-Myc Rabbit Polyclonal 1:500 Santa Cruz 
β-Actin Mouse AC-40 1:3000 Sigma-Aldrich 
HDAC1 Rabbit Polyclonal 1:1000 Cell Signaling 
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4.6. Quantitative Real-time Reverse Transcription PCR (qRT-PCR) 
Total RNA was isolated using mirVanaTM miRNA isolation kit (Ambion) according to 
the manufacturer’s directions, and RNA concentration was measured by nanodrop 
analysis. cDNA was generated from 1μg of total RNA (denatured for 5 minutes at 65°C) 
in 1.2μl of dNTPs (Invitrogen), 2μl of M-MuLV reverse transcriptase buffer (New 
England Biolabs), 1μl of oligo-DT (Invitrogen), 1μl RNase inhibitor (Promega) and 1μl 
of 200.000 U/ml M-MuLV reverse transcriptase (New England Biolabs) performed at 
42°C for 45 minutes followed by 65°C for 10 minutes using Mater Cycler Pro 
(Eppendorf). cDNA for microRNAs was synthesized from 0.1μg of RNA using 1μl of 
2pM of each stem loop primer. Resulting cDNA was diluted at 1:5 for total RNA gene-
specific amplification, undiluted for microRNA, and 1:100 for housekeeping gene (β-
ACTIN) controls and reaction was setup using 1μl cDNA, 10μl of SYBR green mix 
(Takara), 0.4μl of 10μM forward primer, 0.4μl of 10μM of reverse primer, and 8.2μl of 
water. Reactions were performed in duplicates per cDNA sample using MxPRO 3000 
(Stratagene) (95°C 5 min, 40 cycles [95°C X 25 sec, 62°C X 25 sec, 95°C X 1 min, 62°C 
X 1 min, 95°C X 30 sec). The relative change of transcript amount in each sample was 
determined by normalizing with the β-ACTIN mRNA (or Sno202 for microRNA) 
expression levels using the ∆∆CT method. Primer sequences are listed in Table 3. 
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Table 3: Primers for RT-PCR and qRT-PCR 
Symbol  Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
NOTCH1  GAGGCGTGGCAGACTATGC  CTTGTACTCCGTCAGCGTGA 
ADAM12L  GTTTGGCTTTGGAGGAAGC
ACAG 
TGCAGGCAGAGGCTTCTGAG
G 
ADAM12S CAAGGAGGCCGGATTCTG 
TG 
TCAGATGAGTGTCAGTGA 
HES1 GAGAGGCGGCTAAGGTGTT
TG 
CTGGTGTAGACGGGGATGAC 
β-ACTIN GTTGTCGACGAGCG GCACAGAGCCTGGCCTT 
miR-29a GTGCCGTACTAGCACCATC
TG 
GCGACTTAGCTAACCGATTT
C 
miR-29b GGCGCGTAGCACCATTTGA
AA 
GCGACACTAACCAACACTGA
T 
miR-29c GTGCCGTCCTAGCACCATT
TG 
GCGACTTAGCTAACCGATTT
C 
Sno202 GCTGTACTGACTTGATGAA
AG 
CATCAGATGGAAAAGGCTTC
A 
miR-29b 
stem loop 
GGTTAGACACAAGCGACAC
TAACCAACACT 
 
miR-29ac 
stem loop 
GCTAAGACCATCATGCGAC
TTAGCTAACCG 
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